Inobrodib's first substantial multiple myeloma dataset suggests late-line promise.

But with Brukinsa and degraders looming, will fixed dosing make the difference?

Etentamig is one of several anti-BCMA T-cell engagers seeking attention at ASH.

Phase 2 data show why Merck took the lowest dose of zilo-V into phase 3.

The group presents data with bleximenib plus chemo, but looks behind Kura’s contender.

Enzomenib might be the most promising agent so far, on a cross-trial basis.

JNJ-89853413 is disclosed as the lead in the two companies' 2020 alliance.

In first-line NSCLC the drug beats chemo, and not Keytruda.

And the company might one day follow Galapagos into decentralised manufacturing.